Welcome to the international HTA database

Showing [23368 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ribociclib (breast cancer, combination with fulvestrant) - Addendum to commission A20-22]
2020	Norwegian Institute of Public Health (NIPH)	[Effectiveness of microwave thermotherapy (TUMT) compared to transurethral resection of the prostate (TURP) for benign prostatic hyperplasia]
2020	Malaysian Health Technology Assessment (MaHTAS)	Needleless Vacutainer system for blood collection
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Darolutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2020	NIHR Health Services and Delivery Research programme	Variations in the organisation of Early Pregnancy Assessment Units (EPAUs) in the UK and their effects on clinical, service and patient-centred outcomes (VESPA)
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apalutamide (prostate cancer) - Addendum to Commission A20-20]
2020	NIHR Health Technology Assessment programme	Rapid antigen detection and molecular tests for group A streptococcal infections for acute sore throat: systematic reviews and economic evaluation
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Apremilast (Behçet’s disease) - Benefit assessment according to §35a Social Code Book V]
2020	Scottish Health Technologies Group (SHTG)	The SARUS (safer - airway - resuscitation) - CPR hood to protect first responders from biohazards
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Solriamfetol (narcolepsy) - Benefit assessment according to §35a Social Code Book V]
2020	Scottish Health Technologies Group (SHTG)	Dxcover brain cancer liquid biopsy test for early brain cancer detection in primary care
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Naldemedine (opioid-induced constipation) - Benefit assessment according to §35a Social Code Book V]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Romosozumab (osteoporosis) - Addendum to Commission A20-24]
2020	National Committee for Technology Incorporation (CONITEC)	[Dolutegravir for the treatment of pregnant women living with HIV]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ponatinib (chronic myeloid leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2020	National Committee for Technology Incorporation (CONITEC)	[Baricitinib (Olumiant) for patients with moderate to severe active rheumatoid arthritis]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ponatinib (Philadelphia chromosome positive acute lymphoblastic leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)]
2020	Agency for Healthcare Research and Quality (AHRQ)	Care interventions for people living with dementia and their caregivers
2020	NIHR Health Technology Assessment programme	A systematic review of psychological interventions to improve motivation for self-management in people with type 1 and type 2 diabetes
2020	National Committee for Technology Incorporation (CONITEC)	[Mirabegron for the treatment of storage dysfunction in patients with neurogenic bladder]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Talazoparib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2020	NIHR Health Services and Delivery Research programme	Using co-production to improve patient carer and staff experiences in health care organizations: a multi-centre, mixed methods evaluation in inpatient stroke units (CREATE)
2020	National Committee for Technology Incorporation (CONITEC)	[Antimuscarinics (oxybutynin, tolterodine, solifenacin and darifenacin) for the treatment of storage dysfunction in patients with neurogenic bladder]
2020	Agency for Healthcare Research and Quality (AHRQ)	Characteristics of existing asthma self-management education packages
2020	National Committee for Technology Incorporation (CONITEC)	[Photodynamic therapy for non-melanoma skin cancer]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Mogamulizumab (mycosis fungoides or Sézary syndrome) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	National Committee for Technology Incorporation (CONITEC)	[Newborn screening for congenital toxoplasmosis]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brentuximab vedotin (systemic anaplastic large cell lymphoma, first line) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	Agency for Healthcare Research and Quality (AHRQ)	Diagnosis and treatment of clinical Alzheimer's-type dmentia
2020	NIHR Public Health Research (PHR) programme	A woman-centred, tailored SMS-delivered multi-component intervention for weight loss and maintenance of weight loss in the postpartum period: intervention adaptation and pilot RCT
2020	National Committee for Technology Incorporation (CONITEC)	[Riociguat for inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension after surgical treatment]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Trifluridine/tipiracil (colorectal cancer) - Addendum to Commission A20-35]
2020	National Committee for Technology Incorporation (CONITEC)	[Orlistat for weight loss in overweight or obese patients]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Onasemnogene abeparvovec (spinal muscular atrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	NIHR Public Health Research (PHR) programme	A two arm feasibility trial of lifestyle information and Slimming World groups to promote weight management and positive lifestyle behaviour in postnatal women from an ethnically diverse inner city population
2020	National Committee for Technology Incorporation (CONITEC)	[Sibutramine for the treatment of obese patients]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Venetoclax (chronic lymphocytic leukaemia) - Addendum to Commission A20-39]
2020	National Committee for Technology Incorporation (CONITEC)	[Empagliflozin and dapagliflozin for the treatment of type 2 diabetes mellitus]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Brigatinib (non-small cell lung cancer) - Addendum to Commission A20-42]
2020	NIHR Health Services and Delivery Research programme	Evaluating the use of patient experience data to improve the quality of inpatient mental health care
2020	NIHR Health Technology Assessment programme	Interventions based on early intensive applied behaviour analysis for autistic children: a systematic review and cost-effectiveness analysis
2020	National Committee for Technology Incorporation (CONITEC)	[Rifapentine plus isoniazid for treatment of latent mycobacterium tuberculosis infection (LTBI)]
2020	NIHR Health Technology Assessment programme	An extended stroke rehabilitation service for people who have had a stroke: the EXTRAS RCT
2020	NIHR Health Technology Assessment programme	Robot-assisted training compared with an enhanced upper limb therapy programme and with usual care for upper limb functional limitation after stroke: the RATULS three-group RCT
2020	National Committee for Technology Incorporation (CONITEC)	[Tofacitinib citrate for the treatment of moderate to severe ulcerative colitis in adult patients with inadequate response, loss of response or intolerance to previous treatment with conventional synthetic or biological drugs]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Darolutamide (prostate cancer) - Addendum to Commission A20-43]
2020	National Committee for Technology Incorporation (CONITEC)	[Expansion of the use of sirolimus for the treatment of adult patients with lymphangioleiomyomatosis]
2020	Agency for Care Effectiveness (ACE)	Acupuncture for adults with low back pain and neck pain
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ivacaftor (cystic fibrosis, 6 months to < 18 years, with R117H mutation)- Benefit assessment according to §35a Social Code Book V]
2020	NIHR Public Health Research (PHR) programme	The effectiveness of promotional campaigns associated with revised UK drinking guidelines: a prospective evaluation
2020	National Committee for Technology Incorporation (CONITEC)	[Targeted therapies (vemurafenib, dabrafenib, cobimetinib, trametinib) and immunotherapies (ipilimumab, nivolumab, pembrolizumab) for the first-line treatment of advanced (unresectable and metastatic) melanoma]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tezacaftor/ivacaftor (combination with ivacaftor; cystic fibrosis, 12 years and older, F508del mutation, heterozygous) - Benefit assessment according to §35a Social Code Book V]
2020	NIHR Health Technology Assessment programme	Computerised speech and language therapy or attention control added to usual care for people with long-term post-stroke aphasia: the Big CACTUS three-arm RCT
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tezacaftor/ivacaftor (combination with ivacaftor; cystic fibrosis, 12 years and older, F508del mutation, homozygous) - Benefit assessment according to §35a Social Code Book V]
2020	NIHR Health Technology Assessment programme	Risk-based, 6-monthly and 24-monthly dental check-ups for adults: the INTERVAL three-arm RCT
2020	National Committee for Technology Incorporation (CONITEC)	[Personal frequency modulation system for hearing-impaired students at any age and at any academic level]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Fostamatinib (chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2020	Agency for Healthcare Research and Quality (AHRQ)	Impact of community health worker certification on workforce and service delivery for asthma and other selected chronic diseases
2020	National Committee for Technology Incorporation (CONITEC)	[Cytoreductive surgery with hyperthermic chemotherapy in patients with malignant peritoneal mesothelioma]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Encorafenib (colorectal cancer) - Benefit assessment according to §35a Social Code Book V]
2020	National Committee for Technology Incorporation (CONITEC)	[Cytoreductive surgery (peritonectomy) with hyperthermic intraperitoneal chemotherapy (HIPEC)]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Scientific elaboration of a concept for an application-accompanying data collection and analysis for the drug onasemnogene abeparvovec in order to prepare a decision according to §35a (3b) Social Code Book V - Rapid report]
2020	National Committee for Technology Incorporation (CONITEC)	[Exclusion of rifampicin for chemoprophylaxis for contacts of patients with Hansen´s disease]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Caplacizumab (acquired thrombotic thrombocytopenic purpura) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2020	National Committee for Technology Incorporation (CONITEC)	[Ruxolitinib for the treatment of patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis, in people with intermediate-2 or high-risk disease]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Osilodrostat (endogenous Cushing syndrome) - Assessment according to §35a (1), Sentence 11, Social Code Book V]
2020	NIHR Health Technology Assessment programme	Sodium bicarbonate to improve physical function in patients over 60 years with advanced chronic kidney disease: the BiCARB RCT
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ozanimod (relapsing remitting multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2020	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Fall-safe assist. Portable device for falls prevention]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Naldemedine (opioid-induced constipation) - Addendum to Commission A20-45]
2020	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Efficiency of 3D reconstruction in maxillofacial surgery]
2020	NIHR Health Technology Assessment programme	Risk assessments and structured care interventions for prevention of foot ulceration in diabetes: development and validation of a prognostic model
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lung cancer screening using low-dose computed tomography]
2020	Agency for Healthcare Research and Quality (AHRQ)	Interventions for breathlessness in patients with advanced cancer
2020	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of the clinical effectiveness and safety of primary shoulder arthroplasty]
2020	NIHR Health Technology Assessment programme	The Namaste Care intervention to improve the quality of dying for people with advanced dementia living in care homes: a realist review and feasibility study for a cluster randomised controlled trial
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Collagen-covered and periosteum-covered autologous chondrocyte implantation in the knee joint as well as matrix-associated autologous chondrocyte implantation in the knee joint]
2020	Agency for Healthcare Research and Quality (AHRQ)	Interventions for substance use disorders in adolescents: a systematic review
2020	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Halcyon intensity-modulated beam conformal image-guided volumetric radiotherapy system for oncology treatment]
2020	NIHR Health Technology Assessment programme	Non-contact infrared thermometers for measuring body temperature in acutely ill children: a method comparison study
2020	NIHR Health Services and Delivery Research programme	Effects of increased distance to urgent and emergency care facilities resulting from health services reconfiguration: a systematic review
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Decision aid for amputations in diabetic foot syndrome - Rapid Report]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Luspatercept (beta-thalassaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	Agency for Healthcare Research and Quality (AHRQ)	Labor dystocia
2020	Basque Office for Health Technology Assessment (OSTEBA)	[Clinical Practice Guidelines on the diagnosis and treatment of non-serious blunt chest trauma]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Luspatercept (myelodysplastic syndromes) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2020	NIHR Health Technology Assessment programme	CARer-ADministration of as-needed sub-cutaneous medication for breakthrough symptoms in home-based dying patients: a UK study (CARiAD)
2020	Institut national d'excellence en sante et en services sociaux (INESSS)	[Rapid review: alternatives to timolol for the treatment of glaucoma]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ledipasvir/sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V]
2020	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Comparative results of the different screening strategies used for T21, T18 and T13: adaptation of the EUnetHTA assessment]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V]
2020	Agency for Care Effectiveness (ACE)	Sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ixekizumab (spondylitis and spondyloarthritis) - Benefit assessment according to §35a Social Code Book V]
2020	Institute for Clinical Effectiveness and Health Policy (IECS)	[Spyglass® cholangiopancreatoscopy for biliary and pancreatic diseases]
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ravulizumab (atypical haemolytic uraemic syndrome) - Benefit assessment according to §35a Social Code Book V]
2020	Agency for Healthcare Research and Quality (AHRQ)	Management of colonic diverticulitis
2020	NIHR Health Services and Delivery Research programme	Factors influencing the utilisation of free-standing and alongside midwifery units in England: a mixed methods research study
2020	Austrian Institute for Health Technology Assessment (AIHTA)	Update 12 months follow-up: Nusinersen in spinal muscular atrophy ("late onset") in children and adolescents ≥ 6 years
2020	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ixekizumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V]